What was the primary driver of sales growth for Schering-Plough in the third quarter of 2000?

The primary drivers of sales growth were the strong performance of the Allergy & Respiratory segment, particularly the CLARITIN line, and the Anti-infective & Anticancer segment, boosted by INTRON A and REBETOL. International sales also showed significant growth, with a 13% increase in the third quarter.

How is Schering-Plough addressing manufacturing issues affecting its asthma products like VANCERIL and PROVENTIL?

The company has received a Warning Letter from the FDA regarding manufacturing issues at its New Jersey facilities for aerosol products (albuterol and VANCERIL). Schering-Plough is implementing remedial actions at these facilities and is in communication with the FDA. These issues have impacted sales, but the cost of related recalls has not been material to financial results.

What is the company's outlook regarding its ongoing legal proceedings and investigations?

Schering-Plough is involved in numerous legal proceedings and investigations, including antitrust actions, FDA inquiries, and patent disputes, particularly concerning CLARITIN. While the company believes its actions are lawful and is cooperating, it acknowledges that the outcomes are unpredictable and could potentially lead to fines, penalties, or administrative remedies. However, some large class-action antitrust settlements have been reached.

How is the company managing its liquidity and returning capital to shareholders?

The company's liquidity remains sufficient, with net income from operations being the primary source of funds. In the first nine months of 2000, operating activities provided $1.999 billion. Schering-Plough is actively returning capital to shareholders through significant share repurchases ($644 million YTD) and a 12% increase in its quarterly dividend.

MRK 10-Q Quarterly Report Q3 FY2000 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. (MRK), operating as Schering-Plough Corporation for this filing, reported a solid performance for the third quarter and the first nine months of 2000. Net sales increased by 7% to $2.4 billion in the third quarter and by 8% to $7.4 billion year-to-date, demonstrating continued revenue growth driven by key pharmaceutical products. Profitability also saw a healthy upward trend, with net income rising to $591 million for the quarter and $1.85 billion for the nine months. This translated into a 14% increase in diluted earnings per share for the quarter to $0.40 and a 16% increase year-to-date to $1.25. The company highlighted growth in its Allergy & Respiratory and Anti-infective & Anticancer segments, particularly from flagship products like CLARITIN and the INTRON A/REBETOL combination therapy. Despite some challenges, including manufacturing issues affecting certain asthma products and ongoing legal proceedings, the company maintained a positive outlook and sufficient liquidity to meet its operational needs.

Key Highlights

1Consolidated net sales grew 7% year-over-year in Q3 2000 to $2.4 billion and 8% for the nine months to $7.4 billion, with international sales showing particularly strong growth (13% in Q3, 9% YTD).
2Diluted earnings per share (EPS) increased by 14% in Q3 to $0.40 and by 16% year-to-date to $1.25, indicating improved profitability.
3The Allergy & Respiratory segment, driven by CLARITIN and NASONEX, saw sales increase by 6% in Q3 and 8% YTD.
4The Anti-infective & Anticancer segment experienced robust growth (23% in Q3, 21% YTD), largely due to INTRON A and REBETOL for Hepatitis C treatment.
5Research and development (R&D) spending increased by 12% in Q3 and 13% YTD, representing a growing investment in future product pipelines (14.2% of sales in Q3).
6The company reported substantial share repurchases ($644 million YTD) and a 12% increase in its quarterly dividend, demonstrating commitment to returning value to shareholders.
7Significant ongoing legal proceedings and investigations are noted, including antitrust actions, FDA investigations, and patent litigation related to key products like CLARITIN.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2000

Summary

Key Highlights

Frequently Asked Questions